# A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Genetic Obesity

> **NCT06041841** · PHASE2 · UNKNOWN · sponsor: **LG Chem** · enrollment: 4 (estimated)

## Conditions studied

- POMC Deficiency Obesity
- PCSK1 Deficiency Obesity
- LEPR Deficiency Obesity

## Interventions

- **DRUG:** LB54640

## Key facts

- **NCT ID:** NCT06041841
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12
- **Primary completion:** 2024-12
- **Final completion:** 2025-12
- **Target enrollment:** 4 (ESTIMATED)
- **Last updated:** 2023-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06041841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06041841, "A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Genetic Obesity". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06041841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*